Literature DB >> 1540974

Clinical studies on cell-mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-gamma production of lymphocytes.

S Ikemoto1, S Wada, M Kamizuru, N Hayahara, T Kishimoto, M Maekawa.   

Abstract

The authors examined interleukin-2 (IL-2) production and interferon gamma (IFN gamma) production of peripheral blood mononuclear cells in 28 patients with renal cell carcinoma and 17 control subjects. The peripheral blood was obtained prior to the initiation of therapeutic procedures. The patients were divided into two groups according to tumor size, less than or equal to 5 cm and greater than 5 cm. The production of IL-2 and IFN gamma was measured by immunoradiometric assay. As a result, in the patients with tumors greater than 5 cm, IL-2 and IFN gamma production was impaired. However, in the patients with tumors less than or equal to 5 cm, IFN gamma production was enhanced, though IL-2 production was not significantly different from that of the control subjects. There was no significant correlation between IL-2 production and IFN gamma production.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540974     DOI: 10.1007/bf01741548

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  32 in total

1.  Cytolytic and proliferative activity of a permanent T killer cell line.

Authors:  G Dennert
Journal:  Nature       Date:  1979-02-08       Impact factor: 49.962

2.  Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: blastogenic response, interleukin-2 production and interferon-gamma production of lymphocytes.

Authors:  S Ikemoto; T Kishimoto; S Wada; S Nishio; M Maekawa
Journal:  Br J Urol       Date:  1990-04

3.  Humoral cytotoxicity in human renal cell carcinoma.

Authors:  T R Hakala; A E Castro; A Y Elliott; E E Fraley
Journal:  Invest Urol       Date:  1974-03

4.  Lymphocyte subsets in renal carcinoma--a sequential study using monoclonal antibodies.

Authors:  A W Ritchie; K James; H S Micklem; G D Chisholm
Journal:  Br J Urol       Date:  1984-04

5.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

Authors:  K Handa; R Suzuki; H Matsui; Y Shimizu; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

6.  Interferon therapy for the treatment of renal cancer.

Authors:  J A Neidhart
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

7.  In vitro cytotoxicity studies in bladder and renal cell cancer.

Authors:  M M Elhilali; S K Nayak
Journal:  Urology       Date:  1976-05       Impact factor: 2.649

8.  Interleukin 2 dependence of human natural killer (NK) cell activity.

Authors:  W Domzig; B M Stadler; R B Herberman
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

9.  Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients.

Authors:  H J Wanebo; R Pace; S Hargett; D Katz; J Sando
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

10.  Enhanced production of murine interferon gamma by T cells generated in response to bacterial infection.

Authors:  E A Havell; G L Spitalny; P J Patel
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.